Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Blames Sub-Par Dosing For Ingrezza Study Failure

Executive Summary

Neurocrine's stock fell 9% on May 24 after the company said a closely-watched Phase II study for Ingrezza in pediatric Tourette's syndrome failed, but blamed a sub-therapeutic dose for the disappointing results. Most analysts gave the prospects for a higher dose study the benefit of the doubt.

You may also be interested in...



Valbenazine's Consistent But Weak Effect In Tourette Dismays Neurocrine

In "very top-line" Phase IIb data, the magnitude of the treatment effect for valbenazine in children with Tourette syndrome was weaker than expected, and its loss from active development means there will be only a handful of candidates under evaluation for the disorder.

Neurocrine Beats Teva To Tardive Dyskinesia Market With Ingrezza

Neurocrine secured FDA approval for the first drug to treat tardive dyskinesia, a large market that crosses multiple diseases and has blockbuster potential.

Another Elagolix Study Supports AbbVie's NDA, But Which Dose?

A second positive Phase III clinical trial for AbbVie Inc.'s elagolix in the treatment of endometriosis pain in premenopausal women supports a new drug application (NDA) submission to the US FDA in 2017, but it's unknown whether both doses tested in the trials will be viable in the real world.

Topics

Related Companies

UsernamePublicRestriction

Register

WI964848

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel